We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Zymergen Inc. (“Zymergen” or the “Company”) (NASDAQ: ZY), connected with the proposed acquisition of the Company by Ginkgo Bioworks Holdings, Inc. (“Ginkgo”) (NYSE: DNA).  Under the terms of the merger agreement, the Company’s shareholders will receive 0.9179 shares of Ginkgo common stock for each Zymergen share owned, representing implied per-share merger consideration of approximately $2.68 based upon Ginkgo’s July 22, 2022 closing price of $2.92.

Weiss Law is investigating whether (i) Zymergen’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the per-share merger consideration adequately compensates Zymergen’s shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.